Pegfilgrastim
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Pegfilgrastim
- Pegfilgrastim: From Neutropenia Prophylaxis to Severe Nonproliferative Diabetic Retinopathy
Pegfilgrastim: From Neutropenia Prophylaxis to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Pegfilgrastim is a long-acting G-CSF (granulocyte colony-stimulating factor) that stimulates neutrophil production. It is marketed in Singapore as three products, but the data compiled for this report do not list an approved indication text. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but currently there are 0 clinical trials and 0 publications supporting this direction. The prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the Singapore licence records |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general knowledge, pegfilgrastim is a pegylated G-CSF that stimulates neutrophil production, and it is generally used to reduce neutropenia in patients receiving myelosuppressive chemotherapy. It has no established connection to retinal microvascular disease.
A theoretical link exists: G-CSF can mobilise haematopoietic and endothelial progenitor cells, which might influence vascular repair. This is speculative. Neutrophil activation could also worsen retinal inflammation, so the direction of effect is uncertain.
The high score (0.999) is a model prediction only. Other predictions for this drug (for example diabetic retinopathy, diabetic cataract and several cataract subtypes) appear to reflect network proximity to diabetic and eye-related conditions rather than biological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13200P | Neulastim Pre-filled Syringe 6mg/0.6ml | Injection, solution | Not listed |
| SIN16012P | Fulphila Solution for Injection in Prefilled Syringe 6mg/0.6ml | Injection, solution | Not listed |
| SIN16249P | Pelgraz Solution for Injection in pre-filled syringe 6mg/0.6mL | Injection, solution | Not listed |
Safety Considerations
- Drug Interactions: 100 interactions were found, and all of the 20 itemised entries are rated Moderate. They include:
- Antineoplastic and cytotoxic agents: paclitaxel, mercaptopurine, azacitidine, arsenic trioxide, trimetrexate, altretamine
- Targeted and biologic agents: abemaciclib, acalabrutinib, avapritinib, alemtuzumab, aldesleukin, belantamab mafodotin, asparaginase
- Radiopharmaceuticals: iobenguane (I-131), ibritumomab tiuxetan, tositumomab (with and without I-131), fludeoxyglucose (18F)
- Others: pegvaliase, levamisole
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the TxGNN model score. No clinical trials or literature support it, and no established mechanism links pegfilgrastim to diabetic retinopathy. The possible pro-inflammatory effect of neutrophil stimulation on the retina is an unaddressed concern.
To proceed, the following is needed:
- Mechanism of action data and a mechanistic rationale for retinal vascular disease
- Preclinical or observational evidence on G-CSF in diabetic retinopathy, including the risk of retinal inflammation
- The approved indications, warnings and contraindications from the Singapore package inserts
- A route compatibility assessment (the current products are systemic injections, and the required route for this indication has not been defined)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.